9.62

0.21% 0.02

After Hours: 9.62

Karyopharm Therapeutics Inc (KPTI)

Overview News Price History Option Chain Financials Discussions Forecast

Karyopharm Therapeutics Inc stock is traded at $9.62, with a volume of 288.09K. It is up +0.21% in the last 24 hours and up +5.95% over the past month. Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company focused on novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. The company conducts research focused on intracellular communication between the nucleus and cytoplasm and has developed small-molecule compounds that inhibit exportin 1 (XPO1), a nuclear export protein. It is focused on marketing XPOVIO (selinexor).

Previous Close:

$9.60

Open:

$9.6

24h Volume:

288.09K

Relative Volume:

0.57

Market Cap:

$218.02M

Revenue:

$146.07M

Net Income/Loss:

$-196.04M

P/E Ratio:

-0.5788

EPS:

-16.621

Net Cash Flow:

$-75.37M

1W Performance:

-4.61%

1M Performance:

+5.95%

6M Performance:

+30.88%

1Y Performance:

+119.13%

1-Day Range:

$9.20

$9.77

1-Week Range:

$9.20

$10.48

52-Week Range:

$3.6503

$10.99

Karyopharm Therapeutics Inc Stock (KPTI) Company Profile

Name

Karyopharm Therapeutics Inc

Sector

Healthcare (1100)

Industry

Biotechnology (615)

Phone

617-658-0600

Address

85 WELLS AVENUE, NEWTON, MA

Employee

228

Twitter

@Karyopharm

Next Earnings Date

2026-08-10

Latest SEC Filings

KPTI's Discussions on Twitter

Compare KPTI vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
KPTI Karyopharm Therapeutics Inc	9.62	221.42M	146.07M	-196.04M	-75.37M	-16.62
VRTX Vertex Pharmaceuticals Inc	529.59	126.07B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	649.81	65.37B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	916.80	57.70B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	313.04	40.19B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	189.99	39.82B	742.00K	-1.37B	-1.07B	-7.0731

Karyopharm Therapeutics Inc Stock (KPTI) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-10-26	Initiated	Rodman & Renshaw	Buy
Feb-05-26	Initiated	Cantor Fitzgerald	Overweight
Oct-13-25	Upgrade	H.C. Wainwright	Neutral → Buy
Jul-16-25	Downgrade	H.C. Wainwright	Buy → Neutral
Jul-11-25	Resumed	H.C. Wainwright	Buy
Jan-19-23	Initiated	Piper Sandler	Overweight
Nov-04-22	Upgrade	RBC Capital Mkts	Sector Perform → Outperform
Feb-09-22	Upgrade	JP Morgan	Underweight → Neutral
Nov-19-21	Resumed	Morgan Stanley	Equal-Weight
Aug-06-21	Downgrade	JP Morgan	Overweight → Neutral
Aug-06-21	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
Aug-06-21	Downgrade	SVB Leerink	Outperform → Mkt Perform
Jul-02-20	Initiated	Morgan Stanley	Overweight
Mar-04-20	Initiated	Barclays	Overweight
Jan-17-20	Downgrade	Wedbush	Outperform → Neutral
Jul-23-19	Upgrade	JP Morgan	Neutral → Overweight
Jul-05-19	Reiterated	H.C. Wainwright	Buy
Jul-05-19	Reiterated	Robert W. Baird	Outperform
Mar-01-19	Downgrade	JP Morgan	Overweight → Neutral
Feb-28-19	Reiterated	BofA/Merrill	Underperform
Feb-27-19	Downgrade	BofA/Merrill	Neutral → Underperform
Jan-03-19	Upgrade	BofA/Merrill	Underperform → Neutral
Dec-03-18	Initiated	B. Riley FBR	Buy
Nov-09-18	Upgrade	Wedbush	Neutral → Outperform
May-24-18	Downgrade	Wedbush	Outperform → Neutral
Apr-02-18	Resumed	Leerink Partners	Outperform
Nov-15-17	Resumed	H.C. Wainwright	Buy
Sep-15-17	Initiated	RBC Capital Mkts	Outperform
Sep-08-16	Reiterated	H.C. Wainwright	Buy
Aug-30-16	Upgrade	Jefferies	Hold → Buy
Aug-18-16	Initiated	H.C. Wainwright	Buy
Jun-28-16	Initiated	Robert W. Baird	Outperform

View All

Karyopharm Therapeutics Inc Stock (KPTI) Latest News

Jul 01, 2026

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - TradingView

Jul 01, 2026

Karyopharm gives 4 new hires stock awards vesting over 3 years - Stock Titan

Jul 01, 2026

Jun 30, 2026

KPTIKaryopharm Therapeutics Inc Dividends - Finviz

Jun 30, 2026

Jun 29, 2026

Karyopharm Therapeutics Inc.(NasdaqGS:KPTI) added to Russell Small Cap Comp Growth Benchmark - marketscreener.com

Jun 29, 2026

Karyopharm Therapeutics Inc.(NasdaqGS: KPTI) added to Russell 2000 Index - marketscreener.com

Jun 29, 2026

Karyopharm Therapeutics Inc.(NasdaqGS: KPTI) added to Russell 2000 Value Benchmark - marketscreener.com

Jun 29, 2026

Karyopharm Therapeutics Inc.(NasdaqGS: KPTI) added to Russell 2000 Growth Benchmark - marketscreener.com

Jun 29, 2026

Karyopharm Therapeutics Inc.(NasdaqGS: KPTI) added to Russell 3000E Index - marketscreener.com

Jun 29, 2026

Jun 28, 2026

Enterprise value to EBITDA forward of Karyopharm Therapeutics Inc. – NASDAQ:KPTI - TradingView

Jun 28, 2026

Price to sales forward of Karyopharm Therapeutics Inc. – NASDAQ:KPTI - TradingView

Jun 28, 2026

Price to earnings forward of Karyopharm Therapeutics Inc. – NASDAQ:KPTI - TradingView

Jun 28, 2026

Jun 26, 2026

Karyopharm Therapeutics (KPTI) Stock Sees Split Analyst Revisions After Phase 3 Trial Update - Yahoo Finance

Jun 25, 2026

Jun 23, 2026